Reality Check on Immune Globulin (CIDP)
Market access for immune globulin (CIDP) treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, almost 40% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In March 2018, the FDA gave an additional approval to Hizentra (immune globulin subcutaneous [human]) as a maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy to prevent relapse of neuromuscular disability and impairment
- Key Findings: Most health plans consider immune globulin products as undifferentiated brands, therefore finding them hard to manage. The lack of product differentiation, off-label use and provider preference for specific products contribute to limited contracting. To control cost, a few plans specify preferred brands in their policies
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.